Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2017 June;65(3) > Minerva Cardioangiologica 2017 June;65(3):314-20

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Cardioangiologica 2017 June;65(3):314-20

DOI: 10.23736/S0026-4725.16.04287-0

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Transcatheter edge-to-edge mitral valve repair in heart failure

Mathias ORBAN 1, Martin ORBAN 1, Daniel BRAUN 1, Michael NABAUER 1, Steffen MASSBERG 1, 2, Jörg HAUSLEITER 1

1 Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universität München, Munich, Germany; 2 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany


PDF


Heart failure and severe mitral regurgitation (MR) are mutually dependent. Secondary MR is a consequence of chronic heart failure in patients with severely depressed left ventricular ejection fraction (LV-EF) and LV dilatation. Severe MR in heart failure patients worsens prognosis and accelerates LV dilatation and decline in LV-EF. Interventional therapies have changed clinical practice for heart failure patients with secondary MR. In this review we summarize the available data of patients with chronic heart failure undergoing transcatheter edge-to-edge mitral valve repair (TMVR) with the MitraClip® system for severe secondary mitral regurgitation. TMVR could be a therapeutic option with a favorable long-term outcome even in patients with severely depressed LV-EF. Selection criteria predicting mortality in patients undergoing TMVR comprise clinical, laboratory and echocardiographic parameters and can help for clinical decision-making. Ongoing randomized trials will influence the use of interventional treatment of MR in these high-risk patients.


KEY WORDS: Mitral valve insufficiency - Mitral valve annuloplasty - Heart failure

top of page